1987887-92-2 Usage
Description
(Z)-methyl 3-(((4-(methylamino)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate, also known as (3Z)-2,3-dihydro-3-[[[4-(methylamino)phenyl]amino]phenylmethylene]-2-oxo-1H-indole-6-carboxylic acid methyl ester, is a chemical compound that serves as an impurity in the pharmaceutical compound Nintedanib (N478290). This molecule is characterized by its complex structure, which includes an indoline-6-carboxylate core with various substituents, such as a methylamino group and a phenylmethylene group.
Uses
1. Used in Pharmaceutical Industry:
(Z)-methyl 3-(((4-(methylamino)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate is used as an impurity in the production of Nintedanib (N478290), an angiokinase inhibitor. Its presence is significant for the treatment of idiopathic pulmonary fibrosis, a chronic and progressive lung disease characterized by the thickening and stiffening of lung tissue.
2. Used in Cancer Therapy:
(Z)-methyl 3-(((4-(methylamino)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate also inhibits the process of blood vessel formation, which is a critical factor in the growth and metastasis of cancer cells. By inhibiting angiogenesis, (Z)-methyl 3-(((4-(methylamino)phenyl)amino)(phenyl)methylene)-2-oxoindoline-6-carboxylate may assist in cancer therapy by limiting the supply of nutrients and oxygen to tumor cells, thereby slowing their growth and spread.
Check Digit Verification of cas no
The CAS Registry Mumber 1987887-92-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,9,8,7,8,8 and 7 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1987887-92:
(9*1)+(8*9)+(7*8)+(6*7)+(5*8)+(4*8)+(3*7)+(2*9)+(1*2)=292
292 % 10 = 2
So 1987887-92-2 is a valid CAS Registry Number.
1987887-92-2Relevant articles and documents
Harnessing affinity-based protein profiling to reveal a novel target of nintedanib
Chen, Xiong,Li, Manru,Li, Menglin,Wang, Dongmei,Zhang, Jinlan
supporting information, p. 3139 - 3142 (2021/04/02)
Nintedanib (BIBF1120), a triple angiokinase inhibitor, was first approved for idiopathic pulmonary fibrosis (IPF) therapy and is also efficacious for lung carcinoma, and interstitial lung diseases, far beyond its inhibition of VEGFR/PDGFR/FGFR. We identified tripeptidyl-peptidase 1 (TPP1) as one of the direct targets of nintedanib employing the affinity-based protein profiling (AfBPP) technique. This may be a new mechanism for nintedanib's role different from tyrosine kinase inhibition.
